INDV Company Profile and Key Details

Indivior Pharmaceuticals Inc (NASDAQ:INDV) closed at $31.29 USD, losing -$1.23 (-3.78%) from the previous close of $32.52. The stock is currently mid-range between its 52-week high and low $8.69 and $38.00. With a market capitalization of about $3.90 billion, Indivior Pharmaceuticals Inc is classified as a mid-cap and shows market-like volatility (beta ~1.21). Key stats such as the average daily volume over the past year has been around 2.43 million shares, volume is running light vs its 52-week average. Headquartered in North Chesterfield, VA, Indivior Pharmaceuticals Inc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Joseph J. Ciaffoni, the company employs approximately 1,030 people and listed since December 29, 2014. Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence.

Indivior Pharmaceuticals Inc generated EPS of $1.00 over the past year. Five-year average earnings growth is -56.08%. Wall Street analysts project EPS growth of 26.21% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $48.00 to $20.00. The high target offers 45.59% upside. The low target suggests -39.34% downside. The mean target is $32.57. This offers -1.21% upside. Indivior Pharmaceuticals Inc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by -14.32%. The prior quarter beat by 96.15%. Over the last six quarters, Apple has recorded several small beats. These include 10.0% in July 25, 2024.

Indivior Pharmaceuticals Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.19. This means the shares are trading below this model’s fair value.

Indivior Pharmaceuticals Inc has 124.77 million shares outstanding. The public float is 89.80 million shares, elevated short interest at 5.76% of float. This equals 7.12 million shares. The short ratio is 2.08 days. Institutional investors hold 91.47% of the float. Insiders own 3.88%. NINIVAGGI DANIEL A holds 16.92 thousand shares, Stejbach Mark has 16.85 thousand shares and Wheadon David E. has 14.40 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Indivior Pharmaceuticals Inc trades at a P/E ratio of 19.42, slightly below the S&P 500 average, with a price-to-sales ratio of 3.28 and a price-to-book ratio of -41.62 indicating negative book value, which may reflect financial stress. The P/FCF stands at -47.55, also below market averages.

Our AI price prediction model suggests that Indivior Pharmaceuticals Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.18%, with price expected at $33.69 by April 28, 2026, within a range of $32.85 to $34.60 3-Month Outlook: Projected rise of 65.7%, reaching $54.63 by July 13, 2026, with a range of $54.11 to $55.30. 1-Year Outlook: Projected gain of 3.55%, with price at $34.14 by April 14, 2027, within a range of $30.66 to $36.80.

Indivior Pharmaceuticals Inc (NASDAQ:INDV) shares are flat -8.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Indivior Pharmaceuticals Inc trading at a premium to the broader market with a P/E of 19.42. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $26.15, suggesting -20.69% downside. Our AI forecast model points to short-term strength (2.18% over two weeks), a medium-term rise (65.7% over three months), and a longer-term gain (3.55% over one year), with expected trading ranges indicating moderate volatility.